fulvestrant,palbociclib,avelumab
merck,pfizer
['mbc', 'breast', ' fulv', 'avelumab', 'palbo']
exciting data from the #ctc analysis of the pace study. no benefit of fulv+palbo or f+p+avelumab over f in the &lt;5 ctcs group, in patients with 5 ctcs the f+p and f+p+a arms showed improved outcomes compared to f alone. check poster #280! #mbc #asco23 #liquidbiopsy #breastcancer 
Physician scientist, Breast Oncology @CroAviano, @Uniud, @LiquidBioTeam, @CtcLaboratory. #TranslationalResearch, #PrecisionMedicine, Mac Geek, Ramen Addicted.